Literature DB >> 28650232

Pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide in cats after oral, intravenous, and intraperitoneal administration of cyclophosphamide.

Katherine A Stroda, Jacqueline D Murphy, Ryan J Hansen, Lisa Brownlee, Elizabeth A Atencio, Daniel L Gustafson, Susan E Lana.   

Abstract

OBJECTIVE To characterize pharmacokinetics of cyclophosphamide and 4-hydoxycyclophosphamide (4-OHCP) in the plasma of healthy cats after oral, IV, and IP administration of cyclophosphamide. ANIMALS 6 healthy adult cats. PROCEDURES Cats were randomly assigned to receive cyclophosphamide (200 mg/m2) via each of 3 routes of administration (oral, IV, and IP); there was a 30-day washout period between successive treatments. Plasma samples were obtained at various time points for up to 8 hours after administration. Samples were treated with semicarbazide hydrochloride to trap the 4-OHCP in stable form, which allowed for cyclophosphamide and trapped 4-OHCP to be simultaneously measured by use of tandem mass spectrometry. Pharmacokinetic parameters were determined from drug concentration-versus-time data for both cyclophosphamide and 4-OHCP. RESULTS Cyclophosphamide was tolerated well regardless of route of administration. Pharmacokinetic parameters for 4-OHCP were similar after oral, IV, and IP administration. Area under the concentration-time curve for cyclophosphamide was lower after oral administration than after IV or IP administration. CONCLUSIONS AND CLINICAL RELEVANCE Cyclophosphamide can be administered interchangeably to cats as oral, IV, and IP formulations, which should provide benefits with regard to cost and ease of administration to certain feline patients.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28650232      PMCID: PMC6143145          DOI: 10.2460/ajvr.78.7.862

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  12 in total

1.  Simultaneous quantification of cyclophosphamide, 4-hydroxycyclophosphamide, N,N',N"-triethylenethiophosphoramide (thiotepa) and N,N',N"-triethylenephosphoramide (tepa) in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

Authors:  Milly E de Jonge; Selma M van Dam; Michel J X Hillebrand; Hilde Rosing; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Journal:  J Mass Spectrom       Date:  2004-03       Impact factor: 1.982

2.  Combination chemotherapy in feline lymphoma: treatment outcome, tolerability, and duration in 23 cats.

Authors:  D Simon; N Eberle; L Laacke-Singer; I Nolte
Journal:  J Vet Intern Med       Date:  2008-02-29       Impact factor: 3.333

3.  Veterinary Co-operative Oncology Group - Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0.

Authors: 
Journal:  Vet Comp Oncol       Date:  2004-12       Impact factor: 2.613

4.  Bioavailability of cyclophosphamide and vincristine after intraperitoneal administration in cats.

Authors:  Marieke J Voorhorst; Erik M van Maarseveen; Adriaan J van Lankveld; Erik Teske
Journal:  Anticancer Drugs       Date:  2014-11       Impact factor: 2.248

5.  Treatment of feline intermediate- to high-grade lymphoma with a modified university of Wisconsin-Madison protocol: 119 cases (2004-2012).

Authors:  S A Collette; S D Allstadt; E M Chon; W Vernau; A N Smith; L D Garrett; K Choy; R B Rebhun; C O Rodriguez; K A Skorupski
Journal:  Vet Comp Oncol       Date:  2015-06-25       Impact factor: 2.613

6.  Liver disease selectively modulates cytochrome P450--mediated metabolism.

Authors:  Reginald F Frye; Nathalie K Zgheib; Gary R Matzke; Diego Chaves-Gnecco; Mordechai Rabinovitz; Obaid S Shaikh; Robert A Branch
Journal:  Clin Pharmacol Ther       Date:  2006-09       Impact factor: 6.875

Review 7.  Clinical pharmacokinetics of cyclophosphamide.

Authors:  M J Moore
Journal:  Clin Pharmacokinet       Date:  1991-03       Impact factor: 6.447

8.  Chemotherapy with cyclophosphamide, vincristine, and prednisolone (COP) in cats with malignant lymphoma: new results with an old protocol.

Authors:  Erik Teske; Giora van Straten; Ronald van Noort; Gerard R Rutteman
Journal:  J Vet Intern Med       Date:  2002 Mar-Apr       Impact factor: 3.333

9.  Plasma pharmacokinetics of cyclophosphamide and its cytotoxic metabolites after intravenous versus oral administration in a randomized, crossover trial.

Authors:  R F Struck; D S Alberts; K Horne; J G Phillips; Y M Peng; D J Roe
Journal:  Cancer Res       Date:  1987-05-15       Impact factor: 12.701

10.  Feline extranodal lymphoma: response to chemotherapy and survival in 110 cats.

Authors:  S S Taylor; M R Goodfellow; W J Browne; B Walding; S Murphy; S Tzannes; M Gerou-Ferriani; A Schwartz; J M Dobson
Journal:  J Small Anim Pract       Date:  2009-11       Impact factor: 1.522

View more
  3 in total

1.  Kinetics of Cyclophosphamide Metabolism in Humans, Dogs, Cats, and Mice and Relationship to Cytotoxic Activity and Pharmacokinetics.

Authors:  Dominique A Ramirez; Keagan P Collins; Allister E Aradi; Katherine A Conger; Daniel L Gustafson
Journal:  Drug Metab Dispos       Date:  2018-12-19       Impact factor: 3.922

Review 2.  Revisited Cyclophosphamide in the Treatment of Lupus Nephritis.

Authors:  Xiao-Ying Quan; Hao-Tao Chen; Si-Qin Liang; Chen Yang; Cui-Wei Yao; Yong-Zhi Xu; Hua-Feng Liu; Ning An
Journal:  Biomed Res Int       Date:  2022-05-26       Impact factor: 3.246

3.  Determination of O6-Methylguanine in dried blood spot of breast cancer patients after cyclophosphamide administration.

Authors:  Yahdiana Harahap; Athalia Theda Tanujaya; Farhan Nurahman; Aurelia Maria Vianney; Denni Joko Purwanto
Journal:  Heliyon       Date:  2021-07-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.